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Knowledge of the time at which an HIV-infected individual seroconverts, when the immune
system starts responding to HIV infection, plays a vital role in the design and implementation
of interventions to reduce the impact of the HIV epidemic. A number of biomarkers have been
developed to distinguish between recent and long-term HIV infection, based on the antibody
response to HIV. To quantify the recency of infection at an individual level, we propose char-
acterising the growth of such biomarkers from observations from a panel of individuals with
known seroconversion time, using Bayesian mixed effect models. We combine this knowledge
of the growth patterns with observations from a newly diagnosed individual, to estimate the
probability seroconversion occurred in the X months prior to diagnosis. We explore, through a
simulation study, the characteristics of different biomarkers that affect our ability to estimate
recency, such as the growth rate. In particular, we find that predictive ability is improved by
using joint models of two biomarkers, accounting for their correlation, rather than univariate
models of single biomarkers.
1 Introduction
Following infection with the Human Immunodeficiency Virus (HIV), the immune system re-
sponds by producing anti-HIV antibodies of different types at different stages from infection [5],
culminating in what is known as seroconversion, i.e the time at which antibodies are detectable
in blood serum. CD4 counts and viral load traditionally have been used as prognostic biomarkers
of HIV progression [18, 22] but have been less successful for estimating time since infection, due
to their non-monotonic behaviour and the difficulty of observing individuals at the early stages
of infection . In recent years, focussing instead on the antibody response, a number of serological
assays, able to detect different aspects of this diverse response, have been developed with the
goal of distinguishing recent from long-standing infections. Typically, for a specified biomarker,
a threshold is chosen and HIV positive individuals with a measured optical density (OD) be-
low the threshold are classified as recently infected (see [11, 12, 13, 17, 26, 31] and references
therein). This classification has been used to estimate HIV incidence at population level [10, 19].
At an individual level, however, this dichotomization does not allow a clear quantification of the
recency of infection. The type of statement that can be made on recency can only be on average,
based on knowledge of the mean time taken to cross the chosen threshold from seroconversion.
The key question of interest is whether it is possible to make probabilistic statements at
individual-level about the recency of HIV infection. Can biomarker measurements for a newly
diagnosed individual, combined with knowledge of the natural evolution of the biomarker, be
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used to infer the probability, PX , that an individual has seroconverted in the X months prior to
diagnosis? Antibody-response biomarkers increase monotonically and approach a plateau over
time. An example is the Architect Avidity [31], whose growth pattern is shown in Figure 1.
These data are routinely collected from HIV-positive patients attending clinics in Italy. These
patients have known (or well-estimated) seroconversion times, and at each clinic visit following
diagnosis, one or more biomarkers are measured. For such a panel of individuals, the growth
pattern of each biomarker observed can be estimated. Figure 1 shows each individual’s OD
values of Architect Avidity against time since seroconversion, with the estimated mean growth
curve in blue. Given such growth curves and observations on a newly diagnosed individual, how
well can we estimate the seroconversion probability PX?
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Figure 1: Architect Avidity (on logarithmic scale) with the blue line representing the mean
growth pattern.
PX can be derived from the distribution of an individual’s seroconversion time. Up to now,
little attention has been paid to developing methods for estimating individual seroconversion
times. Traditionally, the midpoint between the last negative and the first positive HIV test date
has been adopted as an estimate [1]. A number of authors have considered the use of markers
of immune response to improve the estimation of seroconversion time. [23, 24] fit a Weibull
model to the known seroconversion times of seroconverters, using CD4 counts as a covariate.
The fitted model is then used to impute the unknown seroconversion times for seroprevalent
individuals for whom CD4 counts are available. [7] develop a Bayesian model for estimating
the conditional distribution of time since seroconversion given CD4 counts at the time of the
first positive HIV test. More recently, [29] model the evolution of two non-linearly evolving
biomarkers by using the same functional form for each biomarker, deriving parameter estimates
through a maximum likelihood approach. Resulting estimates are then used via Bayes’ rule to
estimate the distribution of infection time for each individual in their sample. Similarly, [15]
uses a Bayesian bivariate non-linear mixed-effects model, with the same functional form for each
antibody-response biomarker, to estimate the average time spent in the recent infection state.
More recently, [2] models separately the level of a measured biomarker and presence/absence of
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Figure 2: Time-span of the sequence of measurements for each individual i.
recency, assuming that they are independent. These two sources of information are combined
into one conditional probability that the time of infection is recent. However, in reality, levels
or presence of different biomarkers may be correlated and this correlation should be taken into
account in the estimation process.
Our aim is to explore the feasibility of using a limited number of serial measurements of one
or more biomarkers to quantify the recency of HIV infection for any newly diagnosed patient.
Univariate linear and non-linear mixed-effect models to describe the growth patterns of anti-
body response and viral load biomarkers are given in Section 2.1. Joint non-linear mixed-effects
models of bivariate biomarkers are given in Section 2.2. We evaluate the performance of sin-
gle and multiple intrinsically correlated biomarkers in estimating the probability PX of having
seroconverted in the X months prior to HIV diagnosis through a simulation study (Section 3).
Biomarkers with different growth patterns are investigated to evaluate the impact of particular
characteristics, such as the growth rate, on the accuracy of the estimation. Results are reported
in Section 4 and we end with a discussion in Section 5.
2 Biomarker models
Let ykij denote the observed measurement of the random variable Y
k representing the kth biomarker,
for the ith individual at the jth observation time, tij, where i = 1, . . . , n, j = 1, . . . , ni,
k = 1, . . . , K. Assume that the available data for n individuals (see Figure 2) also include
the dates of the last negative and the first positive HIV test, t−vei and t
+ve
i respectively. The
interval [t−vei , t
+ve
i ] is the interval within which individual i has seroconverted, with length
sci = t
+ve
i − t−vei . Note that τi is the time from seroconversion to t+vei and T ∗ij = τi + tij is
the time from seroconversion to the jth measurement.
2.1 Single outcome models
Suppose that a single outcome k is measured on each individual i at each time point tij from
the first positive HIV test date. The observed longitudinal trajectories of biomarker k can be
modelled as
ykij = g(tij + τi, β
k
i ) + 
k
ij (1)
where kij ∼ N(0, σ2k) represent normally distributed measurement errors. Function g(·) repre-
sents the true underlying values of biomarker k and depends on the time since seroconversion
(tij + τi) and random effects β
k
i , that are normally distributed with mean 0 and variance-
covariance matrix Σβk . Different functional forms of g(·) can be used to capture the underlying
evolution of a biomarker of interest. In what follows markers of antibody-response and viral
presence will be considered.
3
2.1.1 Antibody response
Antibody response may evolve linearly over time since seroconversion [14]. Such evolution can
be represented by a linear mixed-effects model with random intercept βk1i and random slope β
k
2i
[6, 8, 27]:
g(tij + τi, β
k
i ) = β
k
1i + β
k
2i(tij + τi) (2)
The intercept represents the value of the biomarker at seroconversion and the slope the growth
rate.
Alternatively, and more commonly, antibody response follows a non-linear trajectory [13, 17,
31? ]. The three-parameter non-linear function used by Sweeting [30] could be adopted to
describe the growth of monotonically increasing biomarkers:
g(tij + τi, β
k
i ) = β
k
1i + (β
k
2i − βk1i) ∗ exp
(− exp(βk3i)(tij + τi)) (3)
This function has intercept βk2i and approaches an asymptote β
k
1i over a period of time. The pa-
rameter βk3i is the logarithm of the rate constant, representing the growth rate for each individual
i.
2.1.2 Viral presence
Viral presence is thought to be exponentially decreasing and approaching a plateau within a
short period after seroconversion [16, 21, 22, 28], as the immune response starts controlling the
infection. A two-parameter exponential decay function could be used to model such trajectories:
g(tij + τi, β
k
i ) = β
k
1i
(
1 + exp
(− βk2i(tij + τi))) (4)
This non-linear function has decay rate βk2i and plateau β
k
1i.
2.2 Bivariate outcome models
Suppose now that two outcomes are measured on each individual i over time from the first
positive HIV test date. The response vector for an individual i at time tij is (y
1
ij, y
2
ij)
T with
y ki = (y
k
i1, y
k
i2, . . . , y
k
ini
)T being the sequence of measurements for each biomarker k and t i =
(ti1, ti2, . . . , tini)
T being the sequence of measurement times. A bivariate joint model for the
response outcomes is: (
y 1i
y 2i
)
=
(
g1 (τi, t i, β
1
i )
g2 (τi, t i, β
2
i )
)
+
(
 1i
 2i
)
(5)
where the  1i , 
2
i are the within-subject measurement errors of the first and second biomarker
respectively and
gk (τi, t i, β
k
i ) =

gk(ti1 + τi, β
k
i )
gk(ti2 + τi, β
k
i )
...
gk(tini + τi, β
k
i )
 , k = 1, 2.
The measurement errors are assumed to be independent and normally distributed with mean 0
and variance-covariance matrix Σ =
(
σ21 I n1i 0
0 σ22 I n2i
)
where I ni denotes the ni× ni identity
matrix. The random effects β 1i , β
2
i follow the joint multivariate normal distribution with mean
4
vector µβ and variance covariance matrix Σβ =
(
Σ1β Σ
12
β
Σ21β Σ
2
β
)
, which is partitioned into four
sub-matrices: (a) Σ1β includes variances and covariances of the random effects for biomarker 1,
(b) Σ2β includes variances and covariances of the random effects for biomarker 2, (c) Σ
12
β = Σ
21
β
includes covariances between random effects of each biomarker, allowing for correlation between
the two biomarkers.
We first consider a bivariate outcome consisting of a linearly and a non-linearly evolving
antibody-response biomarker, for example two different avidity assays [4, 31]. Additionally,
a bivariate outcome of a non-linearly evolving antibody-response biomarker and viral load is
examined.
3 Simulation study
Assume data from a panel of 100 HIV-infected “in-sample” individuals with known serocon-
version times (τi) are available. For each individual, measurements of biomarkers of antibody
response and viral load are taken at HIV diagnosis and regularly thereafter. The information
provided by the “in-sample” individuals is used to model the dynamics of biomarkers of inter-
est. A new “out-of-sample” individual, with unknown seroconversion time in the seroconversion
interval [t−vei , t
+ve
i ], is diagnosed in a healthcare facility. For this new individual, a number of
biomarkers are measured at HIV diagnosis and every few weeks thereafter.
3.1 Generating simulated datasets
We simulate 100 datasets, each consisting of 100 “in-sample” and 5 “out-of-sample” individu-
als. All “in-sample” individuals are assumed to be observed every three months from the first
positive HIV test date to two years thereafter, resulting in nine observed values of univariate
and bivariate outcomes. For each new individual we generate single and bivariate measures at
HIV diagnosis, two weeks and one month afterwards. We use smaller time intervals between
consecutive measurements for new individuals to investigate the feasibility of recency quantifi-
cation within a reasonably short period after HIV diagnosis. The length of the seroconversion
interval is assumed to be one year for both the “in-sample” and “out-of-sample” individuals.
The seroconversion time for the “in-sample” individuals is generated uniformly from the sero-
conversion interval, τi ∼ U(0, 1), i ∈ 1, . . . , 100. The seroconversion time for the “out-of-sample”
individuals is set to be five days (0.014 years), three months (0.250 years), six months (0.500
years), nine months (0.750 years) and 360 days (0.986 years) respectively before the first positive
HIV test date.
Univariate and bivariate realizations of antibody response and viral load are generated by
using equations (1) and (5) with values of growth parameters as in Table 1. In this “realistic
scenario”, the mean and variance of the random effects for univariate outcomes are chosen so
as to resemble the log-transformed trajectories of existing biomarkers of antibody response, such
as the Avidity Index, LAg Avidity and viral load [1, 13, 14, 17, 31? ]. We generate one linearly
(AR1) and three non-linearly (AR2, AR3, AR4) evolving biomarkers of antibody response with
their mean trajectories shown in Figure 3. The asymptote of each non-linearly evolving antibody-
response biomarker is a fixed effect for all individuals. Biomarkers AR2, AR3, and AR4 differ in
terms of their growth rates, asymptotes and intercepts. In particular, biomarker AR4 is steeper
compared to biomarkers AR2 and AR3 and has a higher asymptote.
Bivariate outcomes of two antibody-response biomarkers are assumed to have positively cor-
related intercepts (ρ = 0.1) and growth rates (ρ = 0.5, see Table 1). High initial viral load may
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Table 1: Parameter values for generating univariate and bivariate outcomes under the realistic
scenario.
Model Mean Variance-Covariance Measurement error
matrix of random effects
Antibody Response
AR1 µβAR1 = (5, 2) ΣβAR1 =
(
0.5000 −0.1900
−0.1900 0.2000
)
σAR1 = 0.1000
AR2 µβAR2 = (0,−1, 1) ΣβAR2 =
0.0000 0.0000 0.00000.0000 0.2000 −0.0850
0.0000 −0.0850 0.4000
 σAR2 = 0.0500
AR3 µβAR3 = (0,−1.5, 0.5) ΣβAR3 = ΣβAR2 σAR3 = 0.0500
AR4 µβAR4 = (1.5,−1.5, 0.8) ΣβAR4 =
0.0000 0.0000 0.00000.0000 0.4000 −0.1470
0.0000 −0.1470 0.6000
 σAR4 = 0.0500
Joint model AR1 & AR4 µβ = (1.5,−1.5, 0.8, 5, 2) Σβ =

0.0000 0.0000 0.0000 0.0000 0.0000
0.0000 0.4000 −0.1470 0.0450 −0.0280
0.0000 −0.1470 0.6000 −0.0550 0.1730
0.0000 0.0450 −0.0550 0.5000 −0.1900
0.0000 −0.0280 0.1730 −0.1900 0.2000
 Σ =
(
0.0025 0
0 0.0100
)
Viral load
VL µβV L = (3, 2) ΣβV L =
(
1.0000 0.3536
0.3536 0.5000
)
σV L = 0.2000
Joint model AR4 & VL µβ = (1.5,−1.5, 0.8, 3, 2) Σβ =

0.0000 0.0000 0.0000 0.0000 0.0000
0.0000 0.4000 −0.1470 0.0630 0.1340
0.0000 −0.1470 0.6000 0.2320 0.0550
0.0000 0.0630 0.2320 1.0000 0.3536
0.0000 0.1340 0.0550 0.3536 0.5000
 Σ =
(
0.0025 0
0 0.0400
)
trigger rapid growth of antibodies; conversely, high initial antibody response may induce a rapid
decline in viral load. We therefore assume that viral load intercepts and antibody growth rates
are positively correlated (ρ = 0.3); as are antibody intercepts and viral load declines (ρ = 0.3).
Subject-specific trajectories of bivariate outcomes, generated using equation (5) and parameter
values presented in Table 1, are shown in Figure 4.
The growth model parameters may affect the ability of antibody-response biomarkers and viral
load to quantify the recency of HIV infection. For linearly evolving biomarkers, where the slope
defines the change in biomarker values over time, a steep slope results in mean values differing
at consecutive time points. Thus, the mean at each time point may be strongly related to a
particular seroconversion time. For non-linearly evolving biomarkers, given a fixed asymptote,
the intercept along with the growth rate define the time that the asymptote will be approached.
In particular, a rapidly evolving biomarker will approach the asymptote within a short period
after seroconversion. After the asymptote is approached, such a biomarker will no longer be
discriminative of recency. In contrast, a slowly evolving biomarker will approach the asymptote
a long time after seroconversion. However, the mean of such a biomarker may be very similar
at different time points, with values that are challenging to relate to particular seroconversion
times.
3.2 Analysing simulated datasets
The analysis is conducted in a Bayesian framework, using a Markov chain Monte Carlo (MCMC)
algorithm as implemented in OpenBUGS 3.2.3 [20] to obtain the joint posterior distribution
of the parameters of interest. Let pi(·) and p(·) denote the prior and posterior distribution
respectively.
For each individual i we have a vector y ki = (y
k
i1, y
k
i2, . . . , y
k
ini
)T of ni responses of biomarker k
generated from equation (1). The joint probability density function for Y ki = (Y
k
i1, Y
k
i2, . . . , Y
k
ini
)T ,
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Figure 3: Mean dynamics of univariate outcomes. AR1 is linearly-evolving, whereas AR2, AR3
and AR4 represent non-linearly evolving antibody-response biomarkers.
conditional on parameters, is given by:
f(y ki |β ki , t i, τi, σk) = f(yki1, yki2, . . . , ykini |β ki , t i, τi, σk)
= (2pi)−
ni
2 |Σi|
1
2 e−
1
2
(
y ki−gk (τi, t i,β
k
i )
)T
(Σi)
−1
(
y ki−gk (τi, t i,β
k
i )
)
(6)
where Σi = σ
2
k
I nki .
For univariate mixed-effects models, the generic form of the joint posterior distribution is:
p(Θ1 |y k) ∝
n∏
i=1
{
f(y ki |β ki , t i, τi, σk)pi(β ki |µβk ,Σβk)pi(τi)
}
× pi(µβk)pi(Σβk)pi(σk) (7)
where Θ1 =
{
β ki , µβk ,Σβk , σk , τi
}
.
When two outcomes are measured at the same time, for each individual i we have a vector Yi =
(Y 1i1, Y
1
i2, . . . , Y
1
ini
, Y 2i1, Y
2
i2, . . . , Y
2
ini
)T . The joint probability density function for Yi conditional on
parameters, can be expressed as:
f(y 1i , y
2
i |βi 1, βi 2, t i, τi,Σ) = (2pi)−
ni
2 |Σ|
1
2 e−
1
2
(
QTi Σ
−1
 Qi
)
(8)
where Qi =
(
y 1i − g1 (τi, t i, β 1i ), y 2i − g2 (τi, t i, β 2i )
)T
and Σ =
(
σ21 I n1i 0
0 σ22 I n2i
)
.
The generic form of the joint posterior distribution for a bivariate outcome is given by:
p(Θ2 |y 1, y 2) ∝
n∏
i=1
{
f(y 1i , y
2
i |βi 1, βi 2, t i, τi,Σ)pi(τi)pi(β 1i , β 2i |µβ ,Σβ )
}
pi(µβ )pi(Σβ )pi(Σ)
(9)
where Θ2 = {βi 1, βi 2, µβ ,Σβ ,Σ, τi}.
For each simulated dataset, the first 100 individuals are considered as the “in-sample” individ-
uals for whom the seroconversion time (τ1:(n−1)) is known. The analysis is conducted by assuming
that we have only one new individual (n = 101) in each dataset, with unknown seroconversion
time, as shown in Figure 5.
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Figure 4: Subject-specific trajectories of bivariate outcomes as generated for one simulated
dataset.
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ykij
σ2k
µkij
βi
k
βk
µβk Σβk
tij τi
yknj
µknjtnj τn
βn
k
j = 1, . . . , ni
i = 1, . . . , n− 1
j = 1, . . . , nn
Figure 5: Directed acyclic graph depicting the univariate model for the kth biomarker as shown
in equation (1) by assuming that the first n− 1 are the in-sample individuals and the nth is the
new individual. Data are represented by shaded circles and the rest of the nodes are unknown
random variables.
The joint posterior distribution of the univariate model displayed in Figure 5 is therefore:
p(τn,Θ|yk, t, τ1:(n−1)) ∝
n−1∏
i=1
{
f(yki |βik, ti, τi, σ2k)pi(βki |µβk ,Σβk)
}
× f(ykn|βnk, tn, τn, σ2k)pi(βkn|µβk ,Σβk)pi(τn)pi(µβk)pi(Σβk)pi(σk) (10)
where Θ = {βki , µβk ,Σβk , σ2k}. Similarly, the joint posterior distribution for a bivariate outcome
is obtained by replacing yk with y1,y2 and Θ = {β1i ,β2i , µβ,Σβ,Σ}.
Priors
Each new individual is assumed to have unknown seroconversion time occurring in their sero-
conversion interval, τn ∈ [t−ven , t+ven ]. Our a priori belief is therefore that τn ∼ Uniform(0, 1),
since each seroconversion interval is of length 1 year. Vague Gaussian priors, N(0, 106), are
placed on the means of the random effects (µβk , µβ), while σ
2
k
is given an inverse-Gamma prior,
pi(σ2
k
) ∼ IG(2, 0.01). Each variance-covariance matrix of the random effects (Σβk ,Σβ) and of
the measurement error (Σ), is given an inverse-Wishart prior with degrees of freedom equal to
one plus the matrix dimension. These priors effectively place a uniform distribution on each of
the correlation parameters [9].
For each simulated dataset, MCMC samples from the marginal posterior distribution of the
seroconversion time p(τn|y, t, τ1:(n−1)) are obtained. These samples are used to derive posterior
probabilities, PX = Pr(τn ≤ X|y, t, τ1:(n−1)), of a new individual having seroconverted in the
last X years before HIV diagnosis. We evaluate the predictive ability of the proposed models in
quantifying the recency of HIV infection by calculating these probabilities for X = 0.167, 0.333
and 0.5 years before HIV diagnosis (P2, P4 and P6 respectively, corresponding to 2, 4 and 6
months).
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4 Results
4.1 Probability of recent seroconversion
The simulated data are initially analysed assuming that the new individual contributes only
a single measurement taken at HIV diagnosis. The analysis is repeated including consecutive
measurements of the new individual taken either two weeks or one month after HIV diagnosis.
No significant differences are observed when we add consecutive measurements to the estimation
process. We therefore present results based only on the measurements taken at HIV diagnosis.
The distributions of the probabilities P2, P4, P6 are summarized over the 100 simulated datasets
in Figure 6 for each of the 5 “out-of-sample” individuals. For a perfectly discriminatory biomarker,
we would expect these probabilities to lie near 0 or 1 depending on the truth. For instance, P2
should lie around 0 for all patients with true seroconversion occurring more than two months
before HIV diagnosis.
4.1.1 Single outcome
The linearly evolving biomarker AR1 leads to very similar estimates of P2, P4 and P6 for each
new patient. In particular, P2 is estimated to lie below 0.05 even for a new patient with true
seroconversion occurring five days before HIV diagnosis (see Figure 6). A possible explanation
might be that biomarker AR1 is only gradually evolving, so that its observed values are too
similar across time.
The non-linear biomarkers of antibody response with a low asymptote, such as AR2 and AR3,
perform worse compared to AR4 (see Web Appendix C, Figure 8). They lead to flat posterior
distributions of seroconversion time (see Web Appendix B Figures 3-7). On the other hand, AR4
and viral load seem to be quite discriminative, providing strong information on seroconversion
time, especially for seroconversions occurring a few days before HIV diagnosis. However, as
both biomarkers approach their asymptotes, their ability to discriminate the seroconversion
time vanishes. For instance, P6 is greater than 0.6 for patients with long-standing infections,
using the univariate model of viral load.
4.1.2 Bivariate outcomes
The quantification of recency is improved by using joint models of two biomarkers of interest. In
particular, the joint model of AR4 and VL is able to accurately estimate P2 for all new patients.
It leads to estimates above 0.9 and below 0.1 for very recent and long-standing infections respec-
tively. Similar results are obtained when we use a bivariate outcome of two antibody-response
biomarkers. Notably, the combination of AR4 and AR1 leads to the most accurate estimates
of P2, P4 and P6 for those individuals with long-standing infections (see Figure 6). More specif-
ically, it gives estimates of P6 below 0.05 for a new patient with τn = 0.986 years before HIV
diagnosis, compared to 0.2 when a univariate model of AR4 is used. This improvement might
be due to the fact that AR1 is linear and so does not plateau, providing some information on
recency even if HIV diagnosis takes place a long time after infection.
The accuracy of the estimation clearly depends on particular characteristics of biomarkers of
interest, as well as on the timing of the first measurement. If we had to choose only a single
biomarker to quantify recency, we would prefer a rapidly evolving biomarker such as AR4. If
viral load is available, a joint model of antibody response and viral load will lead to more accurate
estimates of the probability of having seroconverted recently. However, even a joint model of
two biomarkers lacks the ability to provide reliable estimates of the recency for all new patients.
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Figure 6: Probability of having seroconverted in the last two, four, and six months before HIV
diagnosis under the realistic scenario. The black dot represents the median and the upper and
lower limits of the error bars show the 25th and 75th percentile of the distribution over the
simulated datasets respectively.
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4.2 Ideal Scenario
A further simulation exercise (see Web Appendix A) reveals that the magnitude of between-
individual heterogeneity has a significant effect on the discriminatory ability of each biomarker
or combination of biomarkers. To investigate this effect, we generated and analysed data as
shown previously, but with the variance of all the random effects being set to 0.01, in an “ideal
scenario”.
We obtain more accurate estimates of the probabilities P2, P4 and P6 for any new individual
(see Figure 7), when univariate and bivariate outcomes are generated under the ideal compared
to the realistic scenario.
4.2.1 Single outcome
Univariate models of AR4 and viral load lead to high values of P2 for recently infected individuals,
and very low values for long-standing infections. The same pattern is observed for P4 when
univariate outcomes are used. However, for a patient with true seroconversion occurring exactly
six months before HIV diagnosis, all univariate outcomes lead to P6 below 0.6 (See Web Appendix
Figure 9).
4.2.2 Bivariate outcomes
Bivariate joint models improve the estimates of P2, P4 and P6 compared to their univariate
counterparts. In particular, for a new patient who has seroconverted a few days (τn = 0.014
years) before HIV diagnosis, the bivariate joint models lead to P2 ≥ 0.95. Furthermore, for
patients who have seroconverted more than two months before HIV diagnosis, both bivariate
models lead to estimates of P2 ≤ 0.05.
For τn = 0.5, all models give a small probability of having seroconverted in the last six months,
with the joint models leading to the smallest estimates. A possible explanation might be that
the non-linear biomarkers of antibody response usually approach their asymptote around the
first six months from seroconversion [4, 30, 31? ]. Therefore, all measurements taken six months
after seroconversion are very similar and are indicative of long-standing infections, but cannot
discriminate the actual time of seroconversion.
5 Discussion
We have investigated a fully Bayesian approach to quantify the recency of HIV infection for a
newly diagnosed individual, using values of one or more biomarkers and information on biomarker
evolution obtained from a panel of HIV-infected individuals. This is the first study to investigate
the ability of biomarkers of both antibody response and viral presence in quantifying recency
at an individual level. We have also explored the characteristics that affect the discriminatory
ability of such biomarkers to provide reliable estimates of the probability of having recently sero-
converted. Linear and non-linear mixed-effects models are used to describe the growth/decline
trajectories of biomarkers. We have introduced a bivariate non-linear mixed-effects model which
allows for different non-linear trends to be modelled simultaneously.
To our knowledge, few studies with their main interest being the estimation of the serocon-
version time have been published, and usually the number of CD4 T-cell counts is used as a
biomarker of interest [7, 23, 24]. Bivariate linear mixed-effects models have been proposed for
markers of immunological and virological status [3, 25, 32] but examples of multivariate non-
linear mixed-models are less common in the context of HIV [15, 29]. The bivariate non-linear
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Figure 7: Probability of having seroconverted in the last two, four, and six months before HIV
diagnosis under the ideal scenario. The black dot represents the median and the upper and lower
limits of the error bars show the 25th and 75th percentile of the distribution over the simulated
datasets respectively.
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Figure 8: Density plots of the posterior distribution of seroconversion time over the simulated
datasets, when we use the antibody response biomarker AR4, the viral load, and their joint
distribution.
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mixed-effects models proposed in Section 2 can be used when the aim of the study is to explore
the association between the evolutions of two non-linear outcomes. The proposed method can
be easily extended to a multivariate non-linear model if more than two outcomes are available.
The results of the simulation study suggest that we are able to learn about the probability
of having recently seroconverted from longitudinal data on biomarkers of recent infection. The
accuracy of the estimation is highly influenced by particular characteristics of markers, as well
as the time of HIV diagnosis. The magnitude of the growth or decline rate plays a vital role
in the estimation, with rapidly-evolving biomarkers (e.g. 3-6 months) providing more precise
estimates of recency. The results indicate also that the level of the asymptote of the non-linear
biomarkers affects their ability to discriminate the recency of infection.
In practice, physicians are interested in using a single biomarker to quantify the recency of
HIV infection, especially if multiple biomarker measures are challenging to obtain due to time
and cost restrictions. Biomarker AR4 seems to provide reliable estimates of the probability of
having recently seroconverted when used in a univariate model. As shown in Web Appendix A:
Figure 1, the distribution of AR4 at different time points overlaps less compared to all the other
single biomarkers. Therefore, we suggest using an antibody-response biomarker similar to AR4,
such as LAg Avidity, if restricted to a single biomarker.
However, we have demonstrated that the use of bivariate joint models improves the quan-
tification of recency. The resulting posterior distributions of seroconversion time for each new
individual that have narrower 95% highest posterior density (HPD) intervals compared to the
univariate models, having accounted for the correlation between biomarkers. A combination
of antibody response and viral load seems to perform slightly better for those seroconvert-
ing up to six months before HIV diagnosis. By contrast, for seroconversions occurring nine
months or almost one year before HIV diagnosis, we obtain marginally better estimates when
two antibody-response biomarkers are used in the estimation process. This result may be due to
both non-linear antibody-response biomarkers and viral load approaching their asymptotes six
months after seroconversion, when they are no longer discriminative. On the other hand, the
antibody-response biomarker AR1, which is linearly evolving, allows the bivariate joint model
to discriminate the seroconversion time for long-standing infections. Overall, we recommend a
combination of two antibody-response biomarkers with different growth patterns, such as AR1
and AR4, to quantify recency of HIV infection.
Surprisingly, no significant differences were found in the quantification of recency when we use
additional bivariate outcomes taken two weeks or one month after HIV diagnosis for each new
individual. It seems that only the first measurement of the bivariate outcome is adequate to
distinguish recency, especially if it is taken soon after seroconversion. On the other hand, the
univariate models become slightly more discriminative with additional information taken every
two weeks after diagnosis (results not shown).
The crucial finding to emerge from the analysis is that the heterogeneity between individuals
plays a vital role in the discriminatory ability of biomarkers of interest. When the between-
subjects variability is reduced to a minimum, the values of the bivariate outcome are indicative
of the seroconversion time. As we increase the between-subjects variability, the biomarkers of
recency become less discriminative, leading to very flat posterior distributions of seroconversion
time. However, it is challenging to find currently existing biomarkers that are as homogeneous
as those generated under the ideal scenario. Researchers developing new and/or alternative
biomarkers for recent infection should aim to find markers that have minimum heterogeneity, if
they are to be valuable for estimation at individual level.
The proposed method is based on specific assumptions about the number and time of mea-
surements, the length of seroconversion intervals, the distribution of random effects and our
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prior beliefs about the parameters of interest. Further work might consider different design of
observation times, leading to unbalanced longitudinal data, or wider seroconversion intervals.
The seroconversion time for the new individual is given a uniform prior which reflects our belief
that seroconversion is equally likely to occur at any time between the last negative and the first
positive HIV test date. If information on testing behaviour is available, it may be incorporated
in the choice of a different prior distribution.
Throughout this paper, we assume that all the information for the in-sample individuals is
available. In practice, we may not have access to all data for the in-sample individuals but
we may only know the posterior distribution of the growth model parameters. In this case, a
two-stage analysis would be more applicable, where this posterior distribution is used as a prior
distribution in the second stage.
Despite the further research required, we have provided a valuable proof-of-concept that fully
Bayesian linear and non-linear mixed effects models for multiple biomarkers may be combined
in joint models to improve estimation of the recency of HIV infection.
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